3 ms·
Now that it's been proven and the manufacturing scaled, there may be a fair bit of profit in it. If tuberculosis, MRSA, and even malaria can be targets, that wo
by jfengel 6y ago
Now that it's been proven and the manufacturing scaled, there may be a fair bit of profit in it. If tuberculosis, MRSA, and even malaria can be targets, that would be world-changing.
I'm not even sure how "cancer" is really a target -- are they talking about individualized treatments for your specific cancer cells?
- jl2718 6y agoThe process generally relies on discovery of potent neoantigens within the somatic mutations and then building mRNA to express it. So, yes, the idea is individualized treatment for cancer. I’m not sure there is any relevance for organism-scale immunity like TB/MRSA/malaria.
- odyssey7 6y agoIt makes sense to me now why this team was so well-positioned to quickly respond to the novel coronavirus. An individualized vaccine for cancer has to be created and administered fast, within the course of a specific patient’s cancer treatment.
- gww 6y agoI imagine that the tumour would quickly evolve to repress expression, mutate, or completely delete the targetted neoantigen as the neoantigen is probably not required for viability.
- jl2718 6y agoThis is absolutely true, and actually the mutations are usually quite diverse already, so it's thought that multiple neoantigens should be targeted simultaneously. However, no matter how much you target, the diversity and evolution of cancer always wins. Therefore, the goal is not to target every last cancer cell, but to trigger enough of an immune response across a wide enough variety of mutations for the B cells to adapt to whatever else they find. This is also the theory of checkpoint blockades, and they will probably be used together.
- gww 6y agoOh I get it that is clever.
- doggodaddo78 6y agoThat's what it sounds like. Possibly safer and simpler than viral immunoconological vectors. I guess the issue is identifying the very specific histological anomalies in cancer cells to target SARS-CoV-2-spikes style. Perhaps this can be done by flow cytometry and sequencing of healthy cells vs. cancer cells. The big challenge is making certain no other cells share the targeted structures.